Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05715229 | Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy(G360-IIT) | terminated | Phase 2 | 5 | Hackensack Meridian HealthOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05789303 | Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma | recruiting | Phase 2 | 83 | University of ChicagoOTHER | 1 | Sep 23, 2026 |
| clinicaltrials |
| NCT05856305 | SCRT in TNT With or Without Chlorophyllin(SCOTCH) | active not recruiting | Phase 2 | 76 | Tata Memorial CentreOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05960773 | Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma | recruiting | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06009926 | Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters | active not recruiting | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06014489 | A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML(HO171) | recruiting | Phase 2 | 142 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06088004 | Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 218 | Suzhou Abogen Biosciences Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06126276 | Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) | recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 2 | Sep 23, 2026 | clinicaltrials |
| NCT06175000 | Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response | recruiting | Phase 2 | 28 | Providence Health & ServicesOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06253650 | Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease(TRINITY) | recruiting | Phase 2 | 46 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06308588 | Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | recruiting | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06553872 | Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL | recruiting | Phase 2 | 60 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06558214 | OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial(OPTIMUS PRIME) | recruiting | Phase 2 | 20 | University of FloridaOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06618287 | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 416 | Bristol-Myers SquibbINDUSTRY | 10 | Sep 23, 2026 | clinicaltrials |
| NCT06629584 | Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06888063 | Additional Chemotherapy Administered Directly Into the Liver Using a Chemo Pump in Patients With Bile Duct Cancer Inside the Liver Treatable by Surgery(PUMP IV) | recruiting | Phase 2 | 40 | Erasmus Medical CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07063745 | A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion(MountainTAP-29) | recruiting | Phase 2 / Phase 3 | 590 | Bristol-Myers SquibbINDUSTRY | 34 | Sep 23, 2026 | clinicaltrials |
| NCT07116616 | A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 190 | ModernaTX, Inc.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07136142 | A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07221357 | A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer | recruiting | Phase 2 / Phase 3 | 990 | Bristol-Myers SquibbINDUSTRY | 25 | Sep 23, 2026 | clinicaltrials |
| NCT07291076 | A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) | recruiting | Phase 1 / Phase 2 | 198 | Bristol-Myers SquibbINDUSTRY | 14 | Sep 23, 2026 | clinicaltrials |
| NCT07293351 | A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) | recruiting | Phase 1 / Phase 2 | 474 | Bristol-Myers SquibbINDUSTRY | 20 | Sep 23, 2026 | clinicaltrials |
| NCT07339176 | Intratumoral N17350 in Advanced Solid Tumors(OP-NEU-101) | recruiting | Phase 1 / Phase 2 | 275 | Onchilles Pharma IncINDUSTRY | 2 | Sep 23, 2026 | clinicaltrials |
| NCT07344220 | Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate(DZ-002-201) | enrolling by invitation | Phase 2 | 39 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07537881 | A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors | recruiting | Phase 1 / Phase 2 | 326 | RemeGen Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07602855 | A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103) | recruiting | Phase 1 / Phase 2 | 184 | GlaxoSmithKlineINDUSTRY | 2 | Sep 23, 2026 | clinicaltrials |
| NCT07631000 | A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer | recruiting | Phase 2 | 37 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07708961 | Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma | suspended | Phase 2 | 60 | Mayo ClinicOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07783594 | Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma | not yet recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07790913 | Obesity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia and Lymphoma | not yet recruiting | Phase 2 | 100 | St. Jude Children's Research HospitalOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07821112 | Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile®(ENDURANCE) | not yet recruiting | Phase 2 | 20 | University of California, IrvineOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07830212 | Diagnostic Performance of ACP3-Targeted PET Imaging in Patients With Primary and Recurrent Prostate Cancer: An Open-Label, Single-Arm, Single-Center Study | not yet recruiting | Phase 2 | 50 | Yong HeOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07835737 | Safety and Efficacy of Folic Acid Combined With Atezolizumab and Bevacizumab as First-Line Therapy for Unresectable Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 78 | West China HospitalOTHER | 0 | Sep 23, 2026 | clinicaltrials |
| NCT07835789 | Testing Repeat Radiation Therapy for Recurrent Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 138 | NRG OncologyOTHER | 0 | Sep 23, 2026 | clinicaltrials |
| NCT07835906 | 68Ga-NYM215 in NENs | not yet recruiting | Phase 1 / Phase 2 | 40 | Peking Union Medical College HospitalOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07836049 | PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC | not yet recruiting | Phase 2 | 20 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07836257 | A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXd | not yet recruiting | Phase 2 | 28 | Fujian Medical UniversityOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07836543 | Trastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung Cancer | not yet recruiting | Phase 2 | 105 | Ming ChenOTHER | 0 | Sep 23, 2026 | clinicaltrials |
| NCT07836712 | Multiple Adjunct Therapies to Improve Immunotherapy Treatment in Patients With Locally Advanced or Metastatic Melanoma or Advanced Hepatocellular Cancer | not yet recruiting | Phase 2 | 46 | University of Southern CaliforniaOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07836777 | Efficacy and Safety of MitoQ in Improving Cancer Cachexia | not yet recruiting | Phase 2 | 20 | The First Affiliated Hospital of Xinxiang Medical CollegeOTHER | 0 | Sep 23, 2026 | clinicaltrials |
| NCT07837622 | A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors | not yet recruiting | Phase 2 | 42 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT00989469 | Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation(NEXIRI) | completed | Phase 1 / Phase 2 | 64 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT01174121 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | recruiting | Phase 2 | 332 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT01857934 | Therapy for Children With Advanced Stage Neuroblastoma | completed | Phase 2 | 153 | St. Jude Children's Research HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT02153957 | Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated With Cranial Radiation for Brain Tumors | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT02314169 | Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer | active not recruiting | Phase 2 | 143 | National Cancer Institute (NCI)NIH | 2 | Sep 22, 2026 | clinicaltrials |
Data updated 6 days agoSource updated Sep 23, 2026source: clinicaltrials